Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
oleh: Nawal Al Kaabi, Yun Kai Yang, Li Fang Du, Ke Xu, Shuai Shao, Yu Liang, Yun Kang, Ji Guo Su, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Xiangfeng Cong, Yao Tan, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Jun Wei Hou, Ze Hua Lei, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-06-01 |
Deskripsi
SARS-CoV-2 variants with immune escape capability highlight the need for the development of cross-neutralising vaccines and regimens. Here, the authors assess the immunogenicity and safety of NVSI-06-08, that integrates antigens from multiple SARS-CoV-2 strains into a single immunogen, as a heterologous booster in adults previously vaccinated with the inactivated vaccine.